Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Total Debt (2016 - 2025)

Historic Total Debt for Ernexa Therapeutics (ERNA) over the last 13 years, with Q3 2025 value amounting to $41000.0.

  • Ernexa Therapeutics' Total Debt fell 9916.77% to $41000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $41000.0, marking a year-over-year decrease of 9916.77%. This contributed to the annual value of $3.0 million for FY2022, which is N/A changed from last year.
  • Per Ernexa Therapeutics' latest filing, its Total Debt stood at $41000.0 for Q3 2025, which was down 9916.77% from $41000.0 recorded in Q2 2025.
  • Ernexa Therapeutics' Total Debt's 5-year high stood at $4.9 million during Q3 2024, with a 5-year trough of $41000.0 in Q2 2025.
  • Moreover, its 5-year median value for Total Debt was $448835.0 (2021), whereas its average is $1.5 million.
  • Its Total Debt has fluctuated over the past 5 years, first crashed by 7549.4% in 2021, then plummeted by 9916.77% in 2025.
  • Ernexa Therapeutics' Total Debt (Quarter) stood at $410000.0 in 2021, then soared by 620.98% to $3.0 million in 2022, then dropped by 14.82% to $2.5 million in 2023, then soared by 95.63% to $4.9 million in 2024, then plummeted by 99.17% to $41000.0 in 2025.
  • Its last three reported values are $41000.0 in Q3 2025, $41000.0 for Q2 2025, and $4.9 million during Q3 2024.